Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jan 14;13(1):73.
doi: 10.3390/vaccines13010073.

Strategic and Technical Considerations in Manufacturing Viral Vector Vaccines for the Biomedical Advanced Research and Development Authority Threats

Lindsay A Parish  1 , Shyam Rele  2 , Kimberly A Hofmeyer  1 , Brooke B Luck  3 , Daniel N Wolfe  4
Affiliations
Review

Strategic and Technical Considerations in Manufacturing Viral Vector Vaccines for the Biomedical Advanced Research and Development Authority Threats

Lindsay A Parish et al. Vaccines (Basel). .

Abstract

Over the past few decades, the world has seen a considerable uptick in the number of new and emerging infectious disease outbreaks. The development of new vaccines, vaccine technologies, and platforms are critical to enhance our preparedness for biological threats and prevent future pandemics. Viral vectors can be an important tool in the repertoire of technologies available to develop effective vaccines against new and emerging infectious diseases. In many instances, vaccines may be needed in a reactive scenario, requiring technologies than can elicit rapid and robust immune responses with a single dose. Here, we discuss how viral vector vaccines are utilized in a vaccine portfolio for priority biological threats, some of the challenges in manufacturing viral vector vaccines, the need to strengthen live virus manufacturing capabilities, and future opportunities to capitalize on the use of viral vectors to improve the sustainability of the Biomedical Advanced Research and Development Authority's vaccine portfolio.

Keywords: BARDA; Biomedical Advanced Research and Development Authority; filoviruses; vaccine manufacturing; vaccine manufacturing sustainability; viral vectors.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. BARDA. [(accessed on 10 December 2024)]; Available online: https://medicalcountermeasures.gov/barda/cbrn/vaccines.
    1. US Department of Health and Human Services. [(accessed on 25 April 2024)]; Available online: https://www.hhs.gov/immunization/basics/types/index.html.
    1. Robert-Guroff M. Replicating and non-replicating viral vectors for vaccine development. Curr. Opin. Biotechnol. 2007;18:546–556. doi: 10.1016/j.copbio.2007.10.010. - DOI - PMC - PubMed
    1. Travieso T., Li J., Mahesh S., Mello J.D.F.R.E., Blasi M. The use of viral vectors in vaccine development. NPJ Vaccines. 2022;7:75. doi: 10.1038/s41541-022-00503-y. - DOI - PMC - PubMed
    1. Coller B.G., Blue J., Das R., Dubey S., Finelli L., Gupta S., Helmond F., Grant-Klein R.J., Liu K., Simon J., et al. Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic. Vaccine. 2017;35 Pt A:4465–4469. doi: 10.1016/j.vaccine.2017.05.097. - DOI - PubMed

LinkOut - more resources